Skip to content
CancerIndex

Publication

Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib.

Authors not recorded

Oncotarget2017PMID 28947956PMC5601124stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (5)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 5

Curated evidence

Evidence citing this paper (6)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
28947956
Run
ING-CIVIC-20260908-000001
Open at source CuratedShowing 1–6 of 6 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
BRAF D594E1
Dabrafenib + TrametinibCombinationLung Non-Small Cell CarcinomaCURATED_BROADERPredictiveDSupports Sensitivity Response3submitted
EID7573

Non-V600 BRAF mutations occur frequently in NSCLC. While BRAF D594E results in impaired kinase activity, it can induce MEK/ERK activation in the presence of RAF1 (CRAF). BEAS-2B lung epithelial cell l… (full text at CIViC)

PMID 28947956 · Noeparast et al., 2017 · Open in CIViC

civic
BRAF D594N1
Dabrafenib + TrametinibCombinationLung Non-Small Cell CarcinomaCURATED_BROADERPredictiveDSupports Sensitivity Response2submitted
EID8820

Non-V600 BRAF mutations occur frequently in NSCLC. While BRAF D594N results in impaired kinase activity, it can induce MEK/ERK activation when expressed in HEK293T cells in the presence of RAF1 (CRAF)… (full text at CIViC)

PMID 28947956 · Noeparast et al., 2017 · Open in CIViC

civic
BRAF G469S1
Dabrafenib + TrametinibCombinationLung Non-Small Cell CarcinomaCURATED_BROADERPredictiveDSupports Sensitivity Response3submitted
EID9515

Non-V600 BRAF mutations occur frequently in NSCLC. BRAF G469S increases kinase activity, as it can induce MEK/ERK activation to higher levels that wild-type BRAF when expressed in HEK293T cells. BEAS-… (full text at CIViC)

PMID 28947956 · Noeparast et al., 2017 · Open in CIViC

civic
BRAF G469V1
Dabrafenib + TrametinibCombinationLung Non-Small Cell CarcinomaCURATED_BROADERPredictiveDSupports Sensitivity Response3submitted
EID9513

Non-V600 BRAF mutations occur frequently in NSCLC. BRAF G469V increases kinase activity, as it can induce MEK/ERK activation to higher levels that wild-type BRAF when expressed in HEK293T cells. BEAS-… (full text at CIViC)

PMID 28947956 · Noeparast et al., 2017 · Open in CIViC

civic
BRAF G596C2
Dabrafenib + TrametinibCombinationLung Non-Small Cell CarcinomaCURATED_BROADERPredictiveDSupports Sensitivity Response2accepted
EID1738

Non-V600 BRAF mutations occur in about half of BRAF-mutated lung cancers, and their sensitivity to Dabrafenib and Trametinib is not well documented. In a cohort of 229 NSCLC patients that underwent mo… (full text at CIViC)

PMID 28947956 · Noeparast et al., 2017 · Open in CIViC

civic
〃Lung Non-Small Cell CarcinomaCURATED_BROADERPredictiveDSupports Sensitivity Response3rejected
EID9514

Non-V600 BRAF mutations occur frequently in NSCLC. While BRAF G596C results in impaired kinase activity, it can induce MEK/ERK activation when expressed in HEK293T cells in the presence of RAF1 (CRAF)… (full text at CIViC)

PMID 28947956 · Noeparast et al., 2017 · Open in CIViC

civic